The introduction of targeted therapy with imatinib and other small-molecule inhibitors that target BCR–ABL1, competing at the level of the ATP binding site of the kinase, has significantly improved the outcome in patients with BCR-ABL1 positive leukemias (An et al., 2010; Biondi et al., 2018). This evidence concerns the gene ABL1 and leukemia.